Mitesh

MHRA Class 2 Medicines Recall: Curaleaf Laboratories, Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD (Rokshaw Ltd) Drug alert number: EL(26)A/13 Date issued: 12 March 2026 Curaleaf Laboratories are recalling three batches of Curaleaf Oil [FS] 10mg/ml THC 10mg/ml CBD (30ml) due to low THC content. DMRC reference number: DMRC-38668711 Company name:Rokshaw Limited Trading as Curaleaf Laboratories [...]

The post MHRA Class 2 Medicines Recall: Curaleaf Laboratories, Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD (Rokshaw Ltd) appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has today (27/02/2026) confirmed the following list of price concessions for February 2026: Please note: Community Pharmacy England has submitted price concession applications for a number of other medicines affected by pricing issues this month. We will issue further updates as soon as we hear back from the Department.  [...]

The post February 2026 Price Concessions 4th Update appeared first on Community Pharmacy England.

The reimbursement prices for the first 11 multi-source products moving from Category C to the new Category H have been published in the March 2026 Drug Tariff. Prices for 6 products have increased whereas 5 products have seen a decrease compared to their previous Category C prices. Ursodeoxycholic acid 500mg tablets (100) has the largest [...]

The post Prices for first 11 Category H products published in the March 2026 Drug Tariff appeared first on Community Pharmacy England.

A falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection has been found supplied through one online pharmacy in the UK. The falsified product is labelled with batch D873576 and applies to Mounjaro KwikPen 15mg solution for injection in pre-filled pen only. The issue was identified due to faults with the pens, where in [...]

The post MHRA Drug Safety Update: Falsified Mounjaro KwikPen 15mg pre-filled pens appeared first on Community Pharmacy England.

Following the completion of a safety review and the recommendations of the Commission on Human Medicines (CHM), the IXCHIQ Chikungunya vaccine is no longer indicated for adults over the age of 60 years, and is contraindicated in all individuals with hypertension, cardiovascular disease, diabetes mellitus, and/or chronic kidney disease. This action follows very rare fatal [...]

The post MHRA Drug Safety Update: IXCHIQ Chikungunya vaccine – updates to restrictions of use following safety review appeared first on Community Pharmacy England.